Equity · US Market · Market Infrastructure

금융 시장 인프라 — 설비가 아니라 인수 · 데이터 · 청산으로 버는 회사들Market infrastructure — companies that earn through acquisitions, data and clearing, not plants金融市場インフラ — 設備ではなく買収・データ・清算で稼ぐ会社

CME 그룹 · ICE · 나스닥 · Cboe · 무디스 · S&P 글로벌 · MSCI · 팩트셋 를 각 회사의 연차 · 분기 보고서(10-K · 10-Q)에서 같은 틀로 편다. 설비투자 회수 · 순자산 배수 대신 이 사업에 맞는 잣대 — 통과 비용을 뺀 순매출, 인수 무형자산 상각 전 이익률, 10년 현금의 쓰임(설비 · 인수 · 자사주 · 배당), 영업권과 자사주가 정하는 장부 자본, 청산 회원의 돈이 실린 재무상태표, FCF 전환과 환원 — 로 본다.CME Group · Intercontinental · Nasdaq · Cboe · Moody's · S&P Global · MSCI · FactSet — laid out in one frame from each company's annual and quarterly reports (10-K · 10-Q). Instead of capex payback and price-to-book, the yardsticks that fit this business: net revenue after pass-through costs, margins before amortization of acquired intangibles, ten years of cash uses (capex, acquisitions, buybacks, dividends), book equity shaped by goodwill and buybacks, balance sheets carrying clearing members' money, and cash conversion and payouts.CME Group · Intercontinental · Nasdaq · Cboe · Moody's · S&P Global · MSCI · FactSetを各社の年次・四半期報告書(10-K・10-Q)から同じ枠組みで展開する。設備投資の回収や株価純資産倍率の代わりに、この事業に合う物差し — 通過費用を差し引いた純売上高、買収無形資産の償却前の利益率、10年間の現金の使い道(設備・買収・自社株買い・配当)、のれんと自社株買いが決める帳簿上の資本、清算会員のお金が載る貸借対照表、FCFへの転換と還元 — で見る。

기준일 2026-11-10As of 2026-11-10基準日 2026-11-1010-K · 10-Q · 8개 회사10-K · 10-Q · 8 companies10-K · 10-Q · 8社거래소 4 · 신용평가 2 · 지수·데이터 2Exchanges 4 · ratings 2 · index & data 2取引所4 · 信用格付け2 · 指数・データ2
Max capex / revenue
6.3%
all eight companies, latest FY
Top margin before amortization
68%
CME Group · net revenue
Ten-year cash acquisitions
22.3$B
Intercontinental
Negative tangible equity
6of 8
equity − goodwill − intangibles < 0
Clearing deposits / assets
80%
CME Group
회계연도는 회사 결산월 기준이고(팩트셋 8월, 나머지 12월) 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값을 쓴다. 거래소의 순매출은 회사가 공시한 '통과 비용을 뺀 매출' 줄이다. 10년 합계는 회계연도 열 해의 합이다. 시세는 쓰지 않았고, 시장 가치는 각 10-K 표지에 적힌 기준일 값 하나뿐이다.Fiscal years follow each company's year-end month (FactSet August, the others December); where the same period appears in several reports, the most recent report's value is used. The exchanges' net revenue is their own 'revenue less pass-through costs' line. Ten-year totals sum ten fiscal years. No market prices are used; the only market value is the figure on each 10-K cover at its reference date.会計年度は各社の決算月ベース(FactSetは8月、他は12月)で、同じ期間が複数の報告書に載る場合は最新の報告書の値を使う。取引所の純売上高は会社が開示する「通過費用を差し引いた売上高」の行。10年合計は10会計年度の合計。株価は使っておらず、市場価値は各10-Kの表紙に記載された基準日の値のみ。
00

한 줄In one line一行で

관측: 설비투자는 여덟 회사 모두 매출의 6% 이하다. 순매출 기준 인수 상각 전 영업이익률 최고는 CME 그룹 68%. 10년 현금 인수 최대는 ICE $22.3B. 자본에서 영업권 · 무형자산을 빼면 6곳이 음수(자본 자체가 음수: MSCI). 청산 예치금이 총자산의 80%인 회사도 있다(CME 그룹).
Observation: capex is at most 6% of revenue at all eight companies. Highest operating margin on net revenue before amortization of acquired intangibles: CME Group 68%. Largest cash acquisitions over ten years: Intercontinental $22.3B. Equity minus goodwill and intangibles is negative at 6 of them (negative equity itself: MSCI). At one company clearing deposits are 80% of total assets (CME Group).
観測:設備投資は8社とも売上高の6%以下。純売上高ベースの買収償却前の営業利益率の最高はCME Group 68%。10年間の現金による買収の最大はIntercontinental $22.3B。資本からのれん・無形資産を引くと6社がマイナス(資本そのものがマイナス:MSCI)。清算預託金が総資産の80%に達する会社もある(CME Group)。
01

무엇을 팔고 무엇에 기대나 — 여덟 회사를 한 표에What they sell and what drives it — eight companies in one table何を売り、何に依存するか — 8社を1つの表に

비교Comparison比較Eight market-infrastructure companies, one table (latest fiscal year)

회사업종FY총매출순매출통과 비용 비중영업이익률(순매출)상각 전 이익률FCFFCF 마진설비투자/매출청산 예치금/자산
CME 그룹거래소FY2025$6.5B$6.5B0%64.9%68.3%$4.2B64.3%1.3%80%
ICE거래소FY2025$12.6B$9.9B21%49.6%59.6%$3.9B39.0%6.3%59%
나스닥거래소FY2025$8.3B$5.2B36%44.4%53.7%$2.0B37.9%3.2%19%
Cboe거래소FY2025$4.7B$2.4B48%60.4%63.3%$1.7B69.2%1.5%17%
무디스신용평가FY2025$7.7B$7.7B—43.4%46.2%$2.6B33.4%4.2%—
S&P 글로벌신용평가FY2025$15.3B$15.3B—42.2%49.2%$5.5B35.6%1.3%—
MSCI지수·데이터FY2025$3.1B$3.1B—54.7%60.1%$1.5B46.5%4.1%—
팩트셋지수·데이터FY2026$2.5B$2.5B—28.3%34.5%$0.7B28.6%4.6%—
CompanyBusinessFYTotal revenueNet revenuePass-through shareOperating margin (net rev.)Margin before amortizationFCFFCF marginCapex/revenueClearing deposits/assets
CME GroupExchangeFY2025$6.5B$6.5B0%64.9%68.3%$4.2B64.3%1.3%80%
IntercontinentalExchangeFY2025$12.6B$9.9B21%49.6%59.6%$3.9B39.0%6.3%59%
NasdaqExchangeFY2025$8.3B$5.2B36%44.4%53.7%$2.0B37.9%3.2%19%
CboeExchangeFY2025$4.7B$2.4B48%60.4%63.3%$1.7B69.2%1.5%17%
Moody'sCredit ratingsFY2025$7.7B$7.7B—43.4%46.2%$2.6B33.4%4.2%—
S&P GlobalCredit ratingsFY2025$15.3B$15.3B—42.2%49.2%$5.5B35.6%1.3%—
MSCIIndex & dataFY2025$3.1B$3.1B—54.7%60.1%$1.5B46.5%4.1%—
FactSetIndex & dataFY2026$2.5B$2.5B—28.3%34.5%$0.7B28.6%4.6%—
会社業種FY総売上高純売上高通過費用の比率営業利益率(純売上高)償却前利益率FCFFCFマージン設備投資/売上高清算預託金/資産
CME Group取引所FY2025$6.5B$6.5B0%64.9%68.3%$4.2B64.3%1.3%80%
Intercontinental取引所FY2025$12.6B$9.9B21%49.6%59.6%$3.9B39.0%6.3%59%
Nasdaq取引所FY2025$8.3B$5.2B36%44.4%53.7%$2.0B37.9%3.2%19%
Cboe取引所FY2025$4.7B$2.4B48%60.4%63.3%$1.7B69.2%1.5%17%
Moody's信用格付けFY2025$7.7B$7.7B—43.4%46.2%$2.6B33.4%4.2%—
S&P Global信用格付けFY2025$15.3B$15.3B—42.2%49.2%$5.5B35.6%1.3%—
MSCI指数・データFY2025$3.1B$3.1B—54.7%60.1%$1.5B46.5%4.1%—
FactSet指数・データFY2026$2.5B$2.5B—28.3%34.5%$0.7B28.6%4.6%—

순매출 규모 순: S&P 글로벌 $15.3B > ICE $9.9B > 무디스 $7.7B > CME 그룹 $6.5B > 나스닥 $5.2B > MSCI $3.1B > 팩트셋 $2.5B > Cboe $2.4B. 인수 무형자산 상각 전 영업이익률 최고는 CME 그룹 68.3%. 설비투자는 여덟 회사 모두 매출의 1.3%~6.3% 사이다.

By net revenue: S&P Global $15.3B > Intercontinental $9.9B > Moody's $7.7B > CME Group $6.5B > Nasdaq $5.2B > MSCI $3.1B > FactSet $2.5B > Cboe $2.4B. Highest operating margin before amortization of acquired intangibles: CME Group 68.3%. Capex is between 1.3% and 6.3% of revenue at all eight.

純売上高の規模の順:S&P Global $15.3B > Intercontinental $9.9B > Moody's $7.7B > CME Group $6.5B > Nasdaq $5.2B > MSCI $3.1B > FactSet $2.5B > Cboe $2.4B。買収無形資産の償却前の営業利益率の最高はCME Group 68.3%。設備投資は8社とも売上高の1.3%〜6.3%。

⚠ 규율: 거래소의 순매출은 회사가 공시한 '통과 비용을 뺀 매출'(회원 리베이트 · 규제 수수료 · 라우팅 비용 차감) 줄이다. CME 는 그런 줄이 없어 총매출 = 순매출이고, 신용평가 · 지수·데이터 회사도 같다. ICE · MSCI 의 설비투자에는 회사가 따로 적는 자체 개발 소프트웨어 투자를 더했다(회사의 FCF 정의와 같게). 회계연도: 팩트셋 FY2026, 나머지 FY2025.

⚠ Discipline: For the exchanges, net revenue is the company's own 'revenue less pass-through costs' line (member rebates, regulatory fees and routing costs deducted). CME has no such line, so its total revenue is its net revenue, as at the ratings, index and data companies. ICE's and MSCI's capex includes the capitalised software development they report separately (matching the companies' own FCF definitions). Fiscal years: FactSet FY2026; the others FY2025.

⚠ 規律:取引所の純売上高は会社が開示する「通過費用を差し引いた売上高」(会員へのリベート・規制手数料・ルーティング費用を控除)の行。CMEはその行がないため総売上高 = 純売上高で、信用格付け・指数・データの会社も同じ。ICE・MSCIの設備投資には会社が別に記載する自社開発ソフトウェアへの投資を加えた(会社のFCFの定義と同じにした)。 会計年度:FactSet FY2026、他はFY2025。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

비교Comparison比較How each company splits its revenue (its own categories, latest fiscal year)

회사구분 축구분과 비중
CME 그룹제품·서비스Clearingandtransactionfees 81% · Market Data 12% · Other 7%
ICE제품·서비스Technology Service 19% · Energy Futures And Options 17% · Mortgage Technology 17% · Fixed Income Data And Analytics 10% · Servicing Software 7% · Origination Technology 6% · …
나스닥부문Market Services 51% · Capital Access Platforms 26% · Financial Technology 23%
Cboe제품·서비스Transaction And Clearing Fees 76% · Access And Capacity Fees 9% · Market Data Fees 7% · Regulatory Fees 6% · Other 2%
무디스제품·서비스Recurring 63% · Transaction 37%
S&P 글로벌제품·서비스Subscription 51% · Non Subscription Transaction 21% · Non Transaction 13% · Asset Linked Fees 8% · Recurring Variable 4% · Sales Usage Based Royalties 3%
MSCI제품·서비스Recurring Subscriptions 73% · Asset Based Fees 25% · Non Recurring 3%
팩트셋부문Americas Segment 65% · EMEA Segment 24% · Asia Pacific Segment 10%
CompanyAxisCategories and shares
CME GroupProduct/serviceClearingandtransactionfees 81% · Market Data 12% · Other 7%
IntercontinentalProduct/serviceTechnology Service 19% · Energy Futures And Options 17% · Mortgage Technology 17% · Fixed Income Data And Analytics 10% · Servicing Software 7% · Origination Technology 6% · …
NasdaqSegmentMarket Services 51% · Capital Access Platforms 26% · Financial Technology 23%
CboeProduct/serviceTransaction And Clearing Fees 76% · Access And Capacity Fees 9% · Market Data Fees 7% · Regulatory Fees 6% · Other 2%
Moody'sProduct/serviceRecurring 63% · Transaction 37%
S&P GlobalProduct/serviceSubscription 51% · Non Subscription Transaction 21% · Non Transaction 13% · Asset Linked Fees 8% · Recurring Variable 4% · Sales Usage Based Royalties 3%
MSCIProduct/serviceRecurring Subscriptions 73% · Asset Based Fees 25% · Non Recurring 3%
FactSetSegmentAmericas Segment 65% · EMEA Segment 24% · Asia Pacific Segment 10%
会社区分の軸区分と比率
CME Group製品・サービスClearingandtransactionfees 81% · Market Data 12% · Other 7%
Intercontinental製品・サービスTechnology Service 19% · Energy Futures And Options 17% · Mortgage Technology 17% · Fixed Income Data And Analytics 10% · Servicing Software 7% · Origination Technology 6% · …
NasdaqセグメントMarket Services 51% · Capital Access Platforms 26% · Financial Technology 23%
Cboe製品・サービスTransaction And Clearing Fees 76% · Access And Capacity Fees 9% · Market Data Fees 7% · Regulatory Fees 6% · Other 2%
Moody's製品・サービスRecurring 63% · Transaction 37%
S&P Global製品・サービスSubscription 51% · Non Subscription Transaction 21% · Non Transaction 13% · Asset Linked Fees 8% · Recurring Variable 4% · Sales Usage Based Royalties 3%
MSCI製品・サービスRecurring Subscriptions 73% · Asset Based Fees 25% · Non Recurring 3%
FactSetセグメントAmericas Segment 65% · EMEA Segment 24% · Asia Pacific Segment 10%

회사가 보고서에 쓰는 구분 그대로다 — '반복 매출' · '거래 매출' · '자산 연동 수수료' 같은 이름과 경계는 회사마다 다르다. 비중은 그 구분의 합을 100으로 놓은 값이다.

These are the categories each company uses in its reports — names and boundaries such as 'recurring', 'transaction' or 'asset-based fees' differ from company to company. Shares are taken over the sum of the categories shown.

各社が報告書で使う区分のまま — 「継続収益」「取引収益」「資産連動手数料」などの名前と境界は会社ごとに異なる。比率は表示した区分の合計を100とした値。

⚠ 규율: 팩트셋은 지역 부문만 공시해 제품·서비스 구분이 없다. 무디스의 부문 매출에는 부문 간 거래가 들어 있다.

⚠ Discipline: FactSet reports geographic segments only, so there is no product split. Moody's segment revenue includes transactions between its segments.

⚠ 規律:FactSetは地域セグメントのみを開示しており、製品の区分がない。Moody'sのセグメント売上高にはセグメント間取引が含まれる。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

02

설비투자 대신 무엇에 돈을 쓰나 — 인수 · 자사주 · 배당Not capex — where the money goes: acquisitions, buybacks, dividends設備投資ではなく何にお金を使うか — 買収・自社株買い・配当

투자Investment投資Capex as a share of revenue: market infrastructure vs. reference companies

Capital expenditure / revenue, latest fiscal yearpercent · Data as of 2026-11-10 · Created 2026-11-140%10%20%30%40%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSetMicrosoftWalmart%+1.3%+6.3%+3.2%+1.5%+4.2%+1.3%+4.1%+4.6%+34.9%+3.7%

여덟 회사의 설비투자는 매출의 최대 6.3%. 비교한 대형 기술·유통 회사는 Microsoft 34.9% · Alphabet 22.7% · Amazon 18.4% · Meta 34.7% · Walmart 3.7%.

Capex at the eight companies is at most 6.3% of revenue. The reference technology and retail companies: Microsoft 34.9% · Alphabet 22.7% · Amazon 18.4% · Meta 34.7% · Walmart 3.7%.

8社の設備投資は売上高の最大6.3%。比較した大手テクノロジー・小売の会社はMicrosoft 34.9% · Alphabet 22.7% · Amazon 18.4% · Meta 34.7% · Walmart 3.7%。

⚠ 규율: 남색 = 금융 시장 인프라 8사, 회색 = 비교 회사. 설비투자는 현금흐름표의 유형자산 취득(ICE · MSCI 는 자체 개발 소프트웨어 포함). 비교 회사의 회계연도는 회사마다 다르다.

⚠ Discipline: Navy = the eight market-infrastructure companies; grey = reference companies. Capex is purchases of property and equipment from the cash flow statement (ICE and MSCI include capitalised software). The reference companies' fiscal years differ.

⚠ 規律:紺 = 金融市場インフラ8社、灰色 = 比較の会社。設備投資はキャッシュフロー計算書の有形固定資産の取得(ICE・MSCIは自社開発ソフトウェアを含む)。比較の会社の会計年度は会社ごとに異なる。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

투자Investment投資Ten years of operating cash flow: where it went

Uses of cash as a share of cumulative operating cash flow, ten fiscal yearspercent of cumulative operating cash flow · Data as of 2026-11-10 · Created 2026-11-140%50%100%150%200%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%CapexCash acquisitionsBuybacksDividends+89.8%+100%+14.7%+70.0%+22.3%+23.4%+130%+80.2%+21.5%+26.9%+141%+31.4%+14.8%+21.5%+73.5%+41.1%+41.6%+24.5%+117%+89.7%+23.3%+126%+18.4%+90.1%+32.5%+149%+48.5%+46.6%+22.0%+129%

10년 영업현금흐름 대비: 현금 인수 최대 나스닥 80% · 자사주 최대 MSCI 90% · 배당 최대 CME 그룹 90%. 네 쓰임의 합이 100%를 넘는 회사는 CME 그룹 100% · ICE 130% · 나스닥 141% · 무디스 117% · S&P 글로벌 126% · MSCI 149% · 팩트셋 129%.

Against ten years of operating cash flow: largest cash acquisitions Nasdaq 80% · largest buybacks MSCI 90% · largest dividends CME Group 90%. Companies whose four uses add up to more than 100%: CME Group 100% · Intercontinental 130% · Nasdaq 141% · Moody's 117% · S&P Global 126% · MSCI 149% · FactSet 129%.

10年間の営業キャッシュフローに対して:現金による買収の最大Nasdaq 80% · 自社株買いの最大MSCI 90% · 配当の最大CME Group 90%。4つの使い道の合計が100%を超える会社はCME Group 100% · Intercontinental 130% · Nasdaq 141% · Moody's 117% · S&P Global 126% · MSCI 149% · FactSet 129%。

⚠ 규율: 100%를 넘는 몫은 차입 · 보유 현금 · 주식 발행으로 메운 것이다. 주식으로 치른 합병(S&P 글로벌의 2022년 합병 등)은 현금이 나가지 않아 이 막대에 없다 — 아래 영업권 카드와 주식 수 카드에 보인다.

⚠ Discipline: Any amount above 100% was financed with borrowing, cash on hand or share issuance. Mergers paid in shares (such as S&P Global's 2022 merger) involve no cash and do not appear in these bars — they show up in the goodwill and share-count cards below.

⚠ 規律:100%を超える分は借入・手元資金・株式発行で賄った分。株式で行った合併(S&P Globalの2022年の合併など)は現金が出ていかないためこの棒にない — 下ののれんと株式数のカードに現れる。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 10개 회계연도 합계(팩트셋 FY2017~FY2026, 나머지 FY2016~FY2025) · 인수 = 인수한 회사의 현금을 뺀 현금 지급액 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Sums over ten fiscal years (FactSet FY2017–FY2026, the others FY2016–FY2025) · acquisitions = cash paid net of the cash acquired · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 10会計年度の合計(FactSet FY2017〜FY2026、他はFY2016〜FY2025)· 買収 = 買収先の現金を差し引いた現金支払額 · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

03

순매출과 이익률 — 인수 상각을 걷어 내고 보면Net revenue and margins — with acquisition amortization set aside純売上高と利益率 — 買収の償却を取り除いて見ると

마진Margin利益率Total revenue vs. net revenue at the four exchanges, latest fiscal year

Total revenue and net revenueUSD billions · Data as of 2026-11-10 · Created 2026-11-1405.010.015.0CME GroupIntercontinentalNasdaqCboeUSD bnTotal revenueNet revenue6.512.68.34.76.59.95.22.4

CME 그룹: 통과 비용 $0.0B(총매출의 0%) · ICE: 통과 비용 $2.7B(총매출의 21%) · 나스닥: 통과 비용 $3.0B(총매출의 36%) · Cboe: 통과 비용 $2.3B(총매출의 48%)

CME Group: pass-through costs $0.0B (0% of total revenue) · Intercontinental: pass-through costs $2.7B (21% of total revenue) · Nasdaq: pass-through costs $3.0B (36% of total revenue) · Cboe: pass-through costs $2.3B (48% of total revenue)

CME Group:通過費用$0.0B(総売上高の0%) · Intercontinental:通過費用$2.7B(総売上高の21%) · Nasdaq:通過費用$3.0B(総売上高の36%) · Cboe:通過費用$2.3B(総売上高の48%)

⚠ 규율: 현물 주식 · 옵션 시장은 거래를 끌어오려고 회원에게 유동성 리베이트를 주고, 규제 수수료(SEC 31조)를 받아 그대로 넘긴다 — 총매출이 거래량과 함께 부풀지만 회사에 남는 몫은 순매출이다.

⚠ Discipline: Cash equity and options markets pay liquidity rebates to members to attract trading and collect regulatory fees (SEC Section 31) that they pass on — total revenue swells with volume, but what the company keeps is net revenue.

⚠ 規律:現物株・オプション市場は取引を呼び込むため会員に流動性リベートを払い、規制手数料(SEC 31条)を受け取ってそのまま渡す — 総売上高は取引量とともに膨らむが、会社に残るのは純売上高。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

마진Margin利益率Operating margin: reported vs. before amortization of acquired intangibles

Operating margin on net revenue, latest fiscal yearpercent of net revenue · Data as of 2026-11-10 · Created 2026-11-140%20%40%60%80%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%Reported (GAAP)Before amortization of acquired intangibles+64.9%+49.6%+44.4%+60.4%+43.4%+42.2%+54.7%+28.3%+68.3%+59.6%+53.7%+63.3%+46.2%+49.2%+60.1%+34.5%

CME 그룹 65% → 68% · ICE 50% → 60% · 나스닥 44% → 54% · Cboe 60% → 63% · 무디스 43% → 46% · S&P 글로벌 42% → 49% · MSCI 55% → 60% · 팩트셋 28% → 35%

CME Group 65% → 68% · Intercontinental 50% → 60% · Nasdaq 44% → 54% · Cboe 60% → 63% · Moody's 43% → 46% · S&P Global 42% → 49% · MSCI 55% → 60% · FactSet 28% → 35%

CME Group 65% → 68% · Intercontinental 50% → 60% · Nasdaq 44% → 54% · Cboe 60% → 63% · Moody's 43% → 46% · S&P Global 42% → 49% · MSCI 55% → 60% · FactSet 28% → 35%

⚠ 규율: 인수한 회사의 고객 관계 · 기술 · 상표 무형자산 상각은 현금이 나가지 않는 비용이다. 상각이 순매출에서 차지하는 몫이 가장 큰 회사는 ICE(10.0%).

⚠ Discipline: Amortization of acquired customer relationships, technology and trade names is a non-cash cost. The company where it takes the largest share of net revenue: Intercontinental (10.0%).

⚠ 規律:買収した顧客関係・技術・商標の無形資産の償却は現金が出ていかない費用。償却が純売上高に占める割合が最も大きい会社はIntercontinental(10.0%)。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

성장Growth成長Net revenue growth: nine-year annual rate vs. latest year

Net revenue growthpercent per year · Data as of 2026-11-10 · Created 2026-11-140%5%10%15%20%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%Compound annual growth, nine yearsLatest fiscal year+6.8%+9.2%+9.7%+17.6%+8.8%+11.7%+11.8%+8.2%+6.4%+7.0%+12.9%+17.2%+8.9%+7.9%+9.7%+6.7%

CME 그룹 연 6.8% · 최근 +6.4% · ICE 연 9.2% · 최근 +7.0% · 나스닥 연 9.7% · 최근 +12.9% · Cboe 연 17.6% · 최근 +17.2% · 무디스 연 8.8% · 최근 +8.9% · S&P 글로벌 연 11.7% · 최근 +7.9% · MSCI 연 11.8% · 최근 +9.7% · 팩트셋 연 8.2% · 최근 +6.7%

CME Group 6.8% a year · latest +6.4% · Intercontinental 9.2% a year · latest +7.0% · Nasdaq 9.7% a year · latest +12.9% · Cboe 17.6% a year · latest +17.2% · Moody's 8.8% a year · latest +8.9% · S&P Global 11.7% a year · latest +7.9% · MSCI 11.8% a year · latest +9.7% · FactSet 8.2% a year · latest +6.7%

CME Group 年6.8% · 直近+6.4% · Intercontinental 年9.2% · 直近+7.0% · Nasdaq 年9.7% · 直近+12.9% · Cboe 年17.6% · 直近+17.2% · Moody's 年8.8% · 直近+8.9% · S&P Global 年11.7% · 直近+7.9% · MSCI 年11.8% · 直近+9.7% · FactSet 年8.2% · 直近+6.7%

⚠ 규율: 인수 효과가 들어 있다 — Cboe 는 2017년 합병 전 한 해가 출발점이라 연평균이 크게 나온다. 보고서에는 인수 효과를 뺀 성장률이 없다.

⚠ Discipline: Acquisitions are included — Cboe's starting year is the one before its 2017 merger, which inflates its annual rate. The reports give no growth figure excluding acquisitions.

⚠ 規律:買収の効果が含まれる — Cboeは2017年の合併前の年が起点のため年平均が大きく出る。報告書には買収の効果を除いた成長率がない。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 9년 연평균 = 첫해(팩트셋 FY2017, 나머지 FY2016)에서 최근 회계연도까지 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Nine-year rate = from the first year (FactSet FY2017, the others FY2016) to the latest fiscal year · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 9年の年平均 = 初年度(FactSet FY2017、他はFY2016)から直近の会計年度まで · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

마진Margin利益率Operating margin before amortization: first three years vs. last three years

Operating margin before amortization of acquired intangiblespercent of net revenue · Data as of 2026-11-10 · Created 2026-11-140%20%40%60%80%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%First three fiscal years, medianLast three fiscal years, median+63.9%+56.3%+44.9%+52.9%+44.3%+46.5%+49.0%+30.5%+67.8%+57.3%+49.2%+61.2%+43.4%+46.9%+59.3%+36.6%

CME 그룹 64% → 68% · ICE 56% → 57% · 나스닥 45% → 49% · Cboe 53% → 61% · 무디스 44% → 43% · S&P 글로벌 47% → 47% · MSCI 49% → 59% · 팩트셋 30% → 37%

CME Group 64% → 68% · Intercontinental 56% → 57% · Nasdaq 45% → 49% · Cboe 53% → 61% · Moody's 44% → 43% · S&P Global 47% → 47% · MSCI 49% → 59% · FactSet 30% → 37%

CME Group 64% → 68% · Intercontinental 56% → 57% · Nasdaq 45% → 49% · Cboe 53% → 61% · Moody's 44% → 43% · S&P Global 47% → 47% · MSCI 49% → 59% · FactSet 30% → 37%

⚠ 규율: 같은 잣대(순매출 · 상각 전)로 10년의 처음과 끝을 본다. 한 해가 아니라 세 해의 가운데 값이라 어느 한 해의 일회성 손익(합의금 · 사업 매각 이익 등)은 빠진다.

⚠ Discipline: The same yardstick (net revenue, before amortization) at the start and end of the decade. The middle value of three years rather than a single year, so a one-off item in any one year (a settlement, a gain on a business sale) drops out.

⚠ 規律:同じ物差し(純売上高・償却前)で10年の最初と最後を見る。1年ではなく3年の中央値のため、どれか1年の一過性の損益(和解金・事業売却益など)は外れる。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 처음 세 해 = 팩트셋 FY2017~FY2019, 나머지 FY2016~FY2018 · 마지막 세 해 = 최근 회계연도까지 · 세 해 가운데 값(두 해뿐이면 평균) · 상각 항목이 빈 해는 뺐다 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: First three years = FactSet FY2017–FY2019, the others FY2016–FY2018 · last three years = up to the latest fiscal year · middle value of the three years (the mean where only two exist) · years without the amortization item are left out · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 最初の3年 = FactSet FY2017〜FY2019、他はFY2016〜FY2018 · 最後の3年 = 直近の会計年度まで · 3年の中央値(2年しかなければ平均)· 償却の項目がない年は除いた · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

04

이익이 현금으로 얼마나 바뀌나How much of the profit turns into cash利益はどれだけ現金に変わるか

현금CashキャッシュFree cash flow as a share of net income: latest year and ten-year total

Free cash flow / net incomepercent · Data as of 2026-11-10 · Created 2026-11-140%50%100%150%200%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%Latest fiscal yearTen-year total+103%+117%+111%+153%+105%+122%+121%+133%+96.6%+113%+129%+151%+109%+118%+118%+118%

CME 그룹 103% (10년 97%) · ICE 117% (10년 113%) · 나스닥 111% (10년 129%) · Cboe 153% (10년 151%) · 무디스 105% (10년 109%) · S&P 글로벌 122% (10년 118%) · MSCI 121% (10년 118%) · 팩트셋 133% (10년 118%)

CME Group 103% (ten years 97%) · Intercontinental 117% (ten years 113%) · Nasdaq 111% (ten years 129%) · Cboe 153% (ten years 151%) · Moody's 105% (ten years 109%) · S&P Global 122% (ten years 118%) · MSCI 121% (ten years 118%) · FactSet 133% (ten years 118%)

CME Group 103%(10年97%) · Intercontinental 117%(10年113%) · Nasdaq 111%(10年129%) · Cboe 153%(10年151%) · Moody's 105%(10年109%) · S&P Global 122%(10年118%) · MSCI 121%(10年118%) · FactSet 133%(10年118%)

⚠ 규율: FCF = 영업현금흐름 − 설비투자. 인수 무형자산 상각처럼 현금이 나가지 않는 비용이 크면 FCF 가 순이익보다 크다. 10년 합계는 손상 · 일회성 손익이 낀 해를 고르게 한다.

⚠ Discipline: FCF = operating cash flow − capex. Large non-cash costs such as amortization of acquired intangibles push FCF above net income. The ten-year total smooths years with impairments or one-off gains and losses.

⚠ 規律:FCF = 営業キャッシュフロー − 設備投資。買収無形資産の償却のように現金が出ていかない費用が大きいとFCFが純利益を上回る。10年合計は減損や一過性の損益のある年をならす。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

현금CashキャッシュFree cash flow margin on net revenue, latest fiscal year

Free cash flow / net revenuepercent · Data as of 2026-11-10 · Created 2026-11-140%20%40%60%80%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%+64.3%+39.0%+37.9%+69.2%+33.4%+35.6%+46.5%+28.6%

CME 그룹 64% · ICE 39% · 나스닥 38% · Cboe 69% · 무디스 33% · S&P 글로벌 36% · MSCI 47% · 팩트셋 29%

CME Group 64% · Intercontinental 39% · Nasdaq 38% · Cboe 69% · Moody's 33% · S&P Global 36% · MSCI 47% · FactSet 29%

CME Group 64% · Intercontinental 39% · Nasdaq 38% · Cboe 69% · Moody's 33% · S&P Global 36% · MSCI 47% · FactSet 29%

⚠ 규율: 순매출 1달러에서 설비투자까지 쓰고 남는 현금. 이자 · 세금은 영업현금흐름에서 이미 빠졌다.

⚠ Discipline: Cash left from each dollar of net revenue after capex. Interest and taxes are already deducted in operating cash flow.

⚠ 規律:純売上高1ドルから設備投資まで使って残る現金。利息・税金は営業キャッシュフローで既に差し引かれている。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

05

장부 자본은 무엇이 정하나 — 영업권과 자사주What sets book equity — goodwill and buybacks帳簿上の資本を決めるもの — のれんと自社株買い

장부Book帳簿Goodwill and intangibles vs. equity, latest fiscal year

Book equity and what it consists ofUSD billions · Data as of 2026-11-10 · Created 2026-11-14-20.0020.040.060.0CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSetUSD bnGoodwill + intangible assetsStockholders' equityEquity minus goodwill and intangibles

자본에서 영업권 · 무형자산을 빼면 음수인 회사 6곳(ICE $-17.1B · 나스닥 $-7.4B · 무디스 $-4.2B · S&P 글로벌 $-9.0B · MSCI $-6.4B · 팩트셋 $-1.1B). 자본 자체가 음수인 회사: MSCI $-2.7B.

Companies whose equity minus goodwill and intangibles is negative: 6 (Intercontinental $-17.1B · Nasdaq $-7.4B · Moody's $-4.2B · S&P Global $-9.0B · MSCI $-6.4B · FactSet $-1.1B). Companies with negative equity itself: MSCI $-2.7B.

資本からのれん・無形資産を引くとマイナスの会社は6社(Intercontinental $-17.1B · Nasdaq $-7.4B · Moody's $-4.2B · S&P Global $-9.0B · MSCI $-6.4B · FactSet $-1.1B)。資本そのものがマイナスの会社:MSCI $-2.7B。

⚠ 규율: 인수 대가는 영업권 · 무형자산으로 장부에 남고, 자사주를 사면 그만큼 자본이 줄어든다. 그래서 이 회사들의 장부 자본은 사업이 버는 힘을 비추지 않는다 — 순자산 배수(P/B) · 자기자본이익률(ROE)은 값을 재는 잣대로 쓸 수 없다.

⚠ Discipline: The price of acquisitions stays on the books as goodwill and intangibles, and buybacks reduce equity by the amount spent. Book equity at these companies therefore does not reflect the earning power of the business — price-to-book (P/B) and return on equity (ROE) cannot serve as valuation yardsticks.

⚠ 規律:買収の対価はのれん・無形資産として帳簿に残り、自社株を買えばその分だけ資本が減る。そのためこれらの会社の帳簿上の資本は事業の稼ぐ力を映さない — 株価純資産倍率(P/B)・自己資本利益率(ROE)は価値を測る物差しとして使えない。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

장부Book帳簿Change in diluted share count over nine years

Diluted weighted-average shares, change over nine yearspercent · Data as of 2026-11-10 · Created 2026-11-14-40%-20%0%20%40%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%+6.3%-4.0%+14.3%+29.1%-7.9%+15.0%-20.6%-7.6%

CME 그룹 +6% · ICE -4% · 나스닥 +14% · Cboe +29% · 무디스 -8% · S&P 글로벌 +15% · MSCI -21% · 팩트셋 -8%

CME Group +6% · Intercontinental -4% · Nasdaq +14% · Cboe +29% · Moody's -8% · S&P Global +15% · MSCI -21% · FactSet -8%

CME Group +6% · Intercontinental -4% · Nasdaq +14% · Cboe +29% · Moody's -8% · S&P Global +15% · MSCI -21% · FactSet -8%

⚠ 규율: 주식으로 치른 합병은 주식 수를 늘리고, 자사주 매입은 줄인다. 같은 10년 동안 자사주를 많이 산 회사도 합병 대가로 주식을 냈으면 주식 수가 늘어난다.

⚠ Discipline: Mergers paid in shares raise the share count; buybacks lower it. A company that bought back many shares over the decade can still show a higher count if it issued shares to pay for a merger.

⚠ 規律:株式で行った合併は株式数を増やし、自社株買いは減らす。同じ10年間に自社株を多く買った会社でも、合併の対価として株式を出せば株式数は増える。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 첫해(팩트셋 FY2017, 나머지 FY2016)와 최근 회계연도의 희석 가중평균 주식수 비교 · 연속한 두 해의 주식수 비가 정수배면 주식 분할로 보고 첫해 값을 맞췄다 (나스닥 3:1 분할 반영) · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Diluted weighted-average shares in the first year (FactSet FY2017, the others FY2016) vs. the latest fiscal year · where the count in two consecutive years differs by a whole multiple, it is treated as a stock split and the first-year count is adjusted (Nasdaq 3-for-1 split applied) · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 初年度(FactSet FY2017、他はFY2016)と直近の会計年度の希薄化後加重平均株式数の比較 · 連続する2年の株式数の比が整数倍なら株式分割とみなし初年度の値を合わせた(Nasdaq 3対1の分割を反映) · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

장부Book帳簿Return on invested capital, including acquired goodwill: first vs. last three years

ROICpercent · Data as of 2026-11-10 · Created 2026-11-140%25%50%75%100%125%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%First three fiscal years, medianLast three fiscal years, median+7.1%+8.8%+8.4%+20.3%+53.7%+111%+23.7%+35.9%+11.1%+7.1%+7.3%+15.8%+26.0%+9.7%+38.0%+19.3%

CME 그룹 7% → 11% · ICE 9% → 7% · 나스닥 8% → 7% · Cboe 20% → 16% · 무디스 54% → 26% · S&P 글로벌 111% → 10% · MSCI 24% → 38% · 팩트셋 36% → 19%

CME Group 7% → 11% · Intercontinental 9% → 7% · Nasdaq 8% → 7% · Cboe 20% → 16% · Moody's 54% → 26% · S&P Global 111% → 10% · MSCI 24% → 38% · FactSet 36% → 19%

CME Group 7% → 11% · Intercontinental 9% → 7% · Nasdaq 8% → 7% · Cboe 20% → 16% · Moody's 54% → 26% · S&P Global 111% → 10% · MSCI 24% → 38% · FactSet 36% → 19%

⚠ 규율: ROIC = 세후 영업이익 / 평균 투하자본(차입 + 자본 + 리스부채 − 현금 · 단기투자). 인수 대가(영업권 · 무형자산)가 투하자본 안에 있어, 인수가 큰 회사일수록 낮게 나온다. 자사주로 자본이 작은 회사는 투하자본이 작아 높게 나온다. 청산 회원 예치금은 회사 현금이 아니라 현금에 넣지 않았다.

⚠ Discipline: ROIC = after-tax operating income / average invested capital (debt + equity + lease liabilities − cash and short-term investments). The price of acquisitions (goodwill and intangibles) sits inside invested capital, so heavy acquirers score lower; buybacks shrink equity and invested capital, so heavy buyers score higher. Clearing members' deposits are not the company's cash and are not counted as cash.

⚠ 規律:ROIC = 税引後営業利益 / 平均投下資本(借入 + 資本 + リース負債 − 現金・短期投資)。買収の対価(のれん・無形資産)が投下資本に含まれるため、買収の大きい会社ほど低く出る。自社株買いで資本が小さい会社は投下資本が小さく高く出る。清算会員の預託金は会社の現金ではないため現金に含めていない。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 세율 = 그해 법인세 / 세전이익 · 처음 세 해 = 팩트셋 FY2017~FY2019, 나머지 FY2016~FY2018 · 마지막 세 해 = 최근 회계연도까지 · 세 해 가운데 값(두 해뿐이면 평균) · 값이 없는 해는 뺐다 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Tax rate = that year's income tax / pre-tax income · first three years = FactSet FY2017–FY2019, the others FY2016–FY2018 · last three years = up to the latest fiscal year · middle value of the three years (the mean where only two exist) · missing years are left out · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 税率 = その年の法人税 / 税引前利益 · 最初の3年 = FactSet FY2017〜FY2019、他はFY2016〜FY2018 · 最後の3年 = 直近の会計年度まで · 3年の中央値(2年しかなければ平均)· 値がない年は除いた · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

06

청산소 — 재무상태표의 대부분은 회원의 돈Clearing houses — most of the balance sheet is members' money清算機関 — 貸借対照表の大半は会員のお金

청산Clearing清算Clearing members' margin and default funds as a share of total assets

Clearing deposits / total assets, latest fiscal yearpercent · Data as of 2026-11-10 · Created 2026-11-140%20%40%60%80%100%CME GroupIntercontinentalNasdaqCboe%+80.5%+59.3%+18.8%+17.4%

CME 그룹 80%($198.4B 중 $159.7B) · ICE 59%($136.9B 중 $81.2B) · 나스닥 19%($31.1B 중 $5.8B) · Cboe 17%($9.3B 중 $1.6B)

CME Group 80% ($198.4B of $159.7B) · Intercontinental 59% ($136.9B of $81.2B) · Nasdaq 19% ($31.1B of $5.8B) · Cboe 17% ($9.3B of $1.6B)

CME Group 80%($198.4Bのうち$159.7B) · Intercontinental 59%($136.9Bのうち$81.2B) · Nasdaq 19%($31.1Bのうち$5.8B) · Cboe 17%($9.3Bのうち$1.6B)

⚠ 규율: 청산소는 회원에게서 증거금과 결제불이행 대비 기금을 받아 맡아 두고, 같은 금액을 부채로 적는다. 자산 대비 지표(자산 회전율 · ROA)는 이 몫을 빼고 봐야 한다.

⚠ Discipline: A clearing house holds margin and default-fund contributions from its members and records the same amount as a liability. Asset-based ratios (asset turnover, ROA) must exclude it.

⚠ 規律:清算機関は会員から証拠金と不履行に備える基金を預かり、同額を負債に計上する。資産に対する指標(資産回転率・ROA)はこの分を除いて見る。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 총자산은 예치금을 실은 같은 보고서의 값 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Total assets are from the same report as the deposits · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 総資産は預託金を載せた同じ報告書の値 · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

청산Clearing清算Non-operating income as a share of pre-tax income

Non-operating income / pre-tax income, latest fiscal yearpercent · Data as of 2026-11-10 · Created 2026-11-14-20%-10%0%10%20%30%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%+20.7%-14.9%-8.6%+6.4%-7.2%-10.2%-14.7%-7.7%

비영업 손익이 세전이익을 가장 크게 늘린 회사는 CME 그룹: 세전이익 $5.3B 가운데 $1.1B(21%). 나머지는 대부분 이자 비용 때문에 음수다.

The company whose pre-tax income gets the biggest lift from non-operating items: CME Group — $5.3B of pre-tax income of $1.1B (21%). Most of the others are negative because of interest expense.

営業外損益が税引前利益を最も大きく押し上げた会社はCME Group:税引前利益$5.3Bのうち$1.1B(21%)。残りは大半が支払利息のためマイナス。

⚠ 규율: CME 의 비영업 손익에는 청산 회원이 맡긴 현금 증거금 · 기금의 운용 수익(회원에게 돌려주는 몫을 따로 비용으로 뺀다)과 지분법 투자 이익이 들어 있다. 회사는 이 운용 수익이 시장 금리와 회원 현금 예치 규모에 따라 움직인다고 적는다.

⚠ Discipline: CME's non-operating income includes earnings on the cash margin and fund contributions deposited by clearing members (the amounts paid back to members are deducted separately) and income from equity-method investments. The company states that this investment income moves with market interest rates and the level of members' cash deposits.

⚠ 規律:CMEの営業外損益には清算会員が預けた現金証拠金・基金の運用収益(会員に返す分は別に費用として差し引く)と持分法投資利益が含まれる。会社はこの運用収益が市場金利と会員の現金預託の規模によって動くと記載している。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 비영업 손익 = 세전이익 − 영업이익 · 세전이익 = 순이익 + 법인세 · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Non-operating income = pre-tax income − operating income · pre-tax income = net income + income tax · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 営業外損益 = 税引前利益 − 営業利益 · 税引前利益 = 純利益 + 法人税 · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

07

현금은 주주에게 — 환원 · 차입 · 시가총액 대비 FCFCash to shareholders — payouts, leverage and FCF against market value現金は株主へ — 還元・借入・時価総額に対するFCF

환원Payout還元Buybacks plus dividends as a share of free cash flow, ten years

Shareholder payouts / free cash flow, ten-year totalspercent · Data as of 2026-11-10 · Created 2026-11-140%50%100%150%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%+93.8%+53.5%+55.1%+38.5%+73.1%+117%+133%+78.2%

CME 그룹 94%(자사주 $0.0B · 배당 $25.3B) · ICE 54%(자사주 $7.1B · 배당 $7.4B) · 나스닥 55%(자사주 $2.9B · 배당 $3.7B) · Cboe 39%(자사주 $1.2B · 배당 $1.8B) · 무디스 73%(자사주 $7.8B · 배당 $4.6B) · S&P 글로벌 117%(자사주 $29.8B · 배당 $7.7B) · MSCI 133%(자사주 $8.4B · 배당 $3.0B) · 팩트셋 78%(자사주 $2.6B · 배당 $1.2B)

CME Group 94% (buybacks $0.0B · dividends $25.3B) · Intercontinental 54% (buybacks $7.1B · dividends $7.4B) · Nasdaq 55% (buybacks $2.9B · dividends $3.7B) · Cboe 39% (buybacks $1.2B · dividends $1.8B) · Moody's 73% (buybacks $7.8B · dividends $4.6B) · S&P Global 117% (buybacks $29.8B · dividends $7.7B) · MSCI 133% (buybacks $8.4B · dividends $3.0B) · FactSet 78% (buybacks $2.6B · dividends $1.2B)

CME Group 94%(自社株買い$0.0B · 配当$25.3B) · Intercontinental 54%(自社株買い$7.1B · 配当$7.4B) · Nasdaq 55%(自社株買い$2.9B · 配当$3.7B) · Cboe 39%(自社株買い$1.2B · 配当$1.8B) · Moody's 73%(自社株買い$7.8B · 配当$4.6B) · S&P Global 117%(自社株買い$29.8B · 配当$7.7B) · MSCI 133%(自社株買い$8.4B · 配当$3.0B) · FactSet 78%(自社株買い$2.6B · 配当$1.2B)

⚠ 규율: 100% 근처면 FCF 를 거의 다 돌려준 것이고, 100% 아래 남은 몫이 현금 인수 · 차입 상환에 쓰였다.

⚠ Discipline: Near 100% means almost all free cash flow was returned; what remains below 100% went to cash acquisitions or debt repayment.

⚠ 規律:100%付近ならFCFをほぼすべて還元したということで、100%を下回る残りは現金による買収・借入の返済に使われた。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 10개 회계연도 합계(팩트셋 FY2017~FY2026, 나머지 FY2016~FY2025) · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Ten fiscal-year totals (FactSet FY2017–FY2026, the others FY2016–FY2025) · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 10会計年度の合計(FactSet FY2017〜FY2026、他はFY2016〜FY2025) · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

환원Payout還元Net debt in years of free cash flow, latest fiscal year

Net debt / free cash flowx · Data as of 2026-11-10 · Created 2026-11-14-2.002.04.06.0CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSetx-0.274.94.2-0.481.82.13.91.6

CME 그룹 -0.3x(순차입 $-1.1B) · ICE 4.9x(순차입 $18.8B) · 나스닥 4.2x(순차입 $8.4B) · Cboe -0.5x(순차입 $-0.8B) · 무디스 1.8x(순차입 $4.5B) · S&P 글로벌 2.1x(순차입 $11.3B) · MSCI 3.9x(순차입 $5.7B) · 팩트셋 1.6x(순차입 $1.1B)

CME Group -0.3x (net debt $-1.1B) · Intercontinental 4.9x (net debt $18.8B) · Nasdaq 4.2x (net debt $8.4B) · Cboe -0.5x (net debt $-0.8B) · Moody's 1.8x (net debt $4.5B) · S&P Global 2.1x (net debt $11.3B) · MSCI 3.9x (net debt $5.7B) · FactSet 1.6x (net debt $1.1B)

CME Group -0.3x(純借入$-1.1B) · Intercontinental 4.9x(純借入$18.8B) · Nasdaq 4.2x(純借入$8.4B) · Cboe -0.5x(純借入$-0.8B) · Moody's 1.8x(純借入$4.5B) · S&P Global 2.1x(純借入$11.3B) · MSCI 3.9x(純借入$5.7B) · FactSet 1.6x(純借入$1.1B)

⚠ 규율: 순차입 = 차입 − 회사 자신의 현금 · 단기투자(청산 회원 예치금 제외). 음수면 차입보다 현금이 많다. 리스부채는 넣지 않았다.

⚠ Discipline: Net debt = borrowings − the company's own cash and short-term investments (clearing members' deposits excluded). Negative means more cash than debt. Lease liabilities are not included.

⚠ 規律:純借入 = 借入 − 会社自身の現金・短期投資(清算会員の預託金を除く)。マイナスなら借入より現金が多い。リース負債は含めていない。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

환원Payout還元Free cash flow against the market value on each 10-K cover

Free cash flow / market value of shares held by non-affiliatespercent · Data as of 2026-11-10 · Created 2026-11-140%2%4%6%8%10%CME GroupIntercontinentalNasdaqCboeMoody'sS&P GlobalMSCIFactSet%+4.2%+3.7%+4.9%+6.9%+3.0%+3.4%+3.4%+8.9%

CME 그룹 4.2%(유통 시가 $98.9B) · ICE 3.7%(유통 시가 $104.4B) · 나스닥 4.9%(유통 시가 $40.6B) · Cboe 6.9%(유통 시가 $24.4B) · 무디스 3.0%(유통 시가 $87.0B) · S&P 글로벌 3.4%(유통 시가 $161.0B) · MSCI 3.4%(유통 시가 $43.1B) · 팩트셋 8.9%(유통 시가 $7.9B)

CME Group 4.2% (market value $98.9B) · Intercontinental 3.7% (market value $104.4B) · Nasdaq 4.9% (market value $40.6B) · Cboe 6.9% (market value $24.4B) · Moody's 3.0% (market value $87.0B) · S&P Global 3.4% (market value $161.0B) · MSCI 3.4% (market value $43.1B) · FactSet 8.9% (market value $7.9B)

CME Group 4.2%(時価$98.9B) · Intercontinental 3.7%(時価$104.4B) · Nasdaq 4.9%(時価$40.6B) · Cboe 6.9%(時価$24.4B) · Moody's 3.0%(時価$87.0B) · S&P Global 3.4%(時価$161.0B) · MSCI 3.4%(時価$43.1B) · FactSet 8.9%(時価$7.9B)

⚠ 규율: 분모는 각 회사가 10-K 표지에 적은 '계열사 외 주주 보유 주식의 시가'(회계연도 중간 기준일 — 12월 결산은 6월 말, 팩트셋은 2월 말)다. 지금 시세가 아니고, 대주주 지분이 큰 회사는 시가총액보다 작다. 이 회사들의 값을 재는 잣대로는 장부 자본이 아니라 FCF 를 쓴다는 뜻으로 싣는다.

⚠ Discipline: The denominator is the market value of shares held by non-affiliates that each company states on its 10-K cover (as of the middle of the fiscal year — end of June for December year-ends, end of February for FactSet). It is not today's price, and for companies with large affiliated holdings it is smaller than market capitalisation. It is shown because free cash flow, not book equity, is the yardstick for valuing these companies.

⚠ 規律:分母は各社が10-Kの表紙に記載する「関係者以外の株主が保有する株式の時価」(会計年度の中間の基準日 — 12月決算は6月末、FactSetは2月末)。現在の株価ではなく、大株主の持分が大きい会社は時価総額より小さい。これらの会社の価値を測る物差しには帳簿上の資本ではなくFCFを使うという意味で載せる。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: FCF = 최근 회계연도 · 시가 = 그 회계연도 10-K 표지의 기준일 값(기준일과 FCF 기간이 다르다) · 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: FCF = latest fiscal year · market value = the figure on that year's 10-K cover, at its own reference date (the date differs from the FCF period) · Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: FCF = 直近の会計年度 · 時価 = その年度の10-K表紙の基準日の値(基準日とFCFの期間は異なる) · 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

08

검증 — Raw Data 상태Verification — data status検証 — データの状態

검증Verification検証Data checks per company

회사최신 제출일통과 / 실패 / 미확인원인 확인된 차이회사 표기 오류 보정
CME 그룹2026-10-23170 / 0 / 201
ICE2026-10-29161 / 0 / 2011
나스닥2026-10-22162 / 0 / 063
Cboe2026-10-30161 / 0 / 240
무디스2026-11-10174 / 0 / 200
S&P 글로벌2026-10-28170 / 0 / 207
MSCI2026-10-20184 / 0 / 000
팩트셋2026-10-26176 / 0 / 104
CompanyLatest filingPassed / failed / unverifiedExplained differencesCompany tagging fixes
CME Group2026-10-23170 / 0 / 201
Intercontinental2026-10-29161 / 0 / 2011
Nasdaq2026-10-22162 / 0 / 063
Cboe2026-10-30161 / 0 / 240
Moody's2026-11-10174 / 0 / 200
S&P Global2026-10-28170 / 0 / 207
MSCI2026-10-20184 / 0 / 000
FactSet2026-10-26176 / 0 / 104
会社最新の提出日合格 / 不合格 / 未確認原因を確認した差会社の表記誤りの補正
CME Group2026-10-23170 / 0 / 201
Intercontinental2026-10-29161 / 0 / 2011
Nasdaq2026-10-22162 / 0 / 063
Cboe2026-10-30161 / 0 / 240
Moody's2026-11-10174 / 0 / 200
S&P Global2026-10-28170 / 0 / 207
MSCI2026-10-20184 / 0 / 000
FactSet2026-10-26176 / 0 / 104

통과 / 실패 / 미확인 = 항등식(자산 = 부채 + 자본, 분기 합 = 연간) · 두 경로 대조 · 제출 원문 재무제표 표 대조의 합계. '원인 확인된 차이' = 공시별 값으로 원인을 확인하고 통과시킨 항목(뒤 보고서의 재작성 · 반올림 등). '회사 표기 오류 보정' = 회사가 단위 · 기간을 잘못 단 값을 버렸거나, 다른 시대의 값이 섞여 4분기를 비운 수.

Passed / failed / unverified = identities (assets = liabilities + equity, sum of quarters = full year) · cross-check of two data paths · cross-check against the tables in the filed reports. 'Explained differences' = items whose cause was traced in the filings and accepted (later restatements, rounding). 'Company tagging fixes' = values dropped because the company tagged a wrong unit or period, or fourth quarters left blank because values from different reporting eras were mixed.

合格 / 不合格 / 未確認 = 恒等式(資産 = 負債 + 資本、四半期の合計 = 通期)· 2つのデータ経路の照合 · 提出された報告書の財務諸表の表との照合の合計。「原因を確認した差」= 開示ごとの値で原因を確認して合格とした項目(後の報告書による修正・端数など)。「会社の表記誤りの補正」= 会社が単位・期間を誤って付けた値を除いたもの、または異なる時期の値が混ざり第4四半期を空欄にした数。

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 회사 연차·분기 보고서(10-K·10-Q) 값 — 같은 기간이 여러 보고서에 실리면 가장 최근 보고서 값 · 회계연도는 회사 결산월 기준(팩트셋 8월, 나머지 12월)이라 같은 12개월이 아니다 · 성장률에는 인수한 회사의 매출이 들어 있다(보고서에 인수 효과를 뺀 숫자가 없다) · 순매출 = 거래소가 공시한 '통과 비용을 뺀 매출' 줄, 그런 줄이 없는 회사는 총매출 · 시세는 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: Values as reported in the companies' annual and quarterly reports (10-K · 10-Q) — where the same period appears in several reports, the most recent report's value · fiscal years follow each company's year-end month (FactSet August, the others December), so they are not the same twelve months · growth includes revenue of acquired businesses (the reports give no figures excluding acquisitions) · net revenue = the exchanges' own 'revenue less pass-through costs' line; companies without such a line use total revenue · no market prices are included.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: U.S. Securities and Exchange Commission (EDGAR).
Limitations: 各社の年次・四半期報告書(10-K・10-Q)の値 — 同じ期間が複数の報告書に載る場合は最新の報告書の値 · 会計年度は各社の決算月ベース(FactSetは8月、他は12月)で同じ12か月ではない · 成長率には買収した会社の売上高が含まれる(報告書に買収の影響を除いた数字がない)· 純売上高 = 取引所が開示する「通過費用を差し引いた売上高」の行、その行がない会社は総売上高 · 株価は載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

∞

천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと

  • 인수 효과를 걸러 내지 못했다. 보고서에 인수한 회사를 뺀 매출 · 이익이 없어 성장률 · 이익률 변화에 인수가 섞여 있다.
  • 회계연도가 다르다. 팩트셋은 8월 결산, 나머지는 12월 결산이다.
  • 순매출의 정의는 거래소가 정한 줄이다. 거래소마다 무엇을 통과 비용으로 보는지가 다르다.
  • S&P 글로벌은 2026년에 한 사업을 떼어 냈다. 최근 회계연도(2025)는 떼어 내기 전 기준이고, 2025년 4분기는 앞뒤 보고서의 기준이 달라 비웠다.
  • 시세를 쓰지 않았다. 유일한 시장 가치는 각 10-K 표지의 기준일 값이다.
  • Acquisitions are not filtered out. The reports give no revenue or profit excluding acquired businesses, so growth and margin changes include acquisitions.
  • Fiscal years differ. FactSet's year ends in August; the others end in December.
  • Net revenue follows each exchange's own line. What counts as a pass-through cost differs between exchanges.
  • S&P Global separated one of its businesses in 2026. The latest fiscal year (2025) is on the pre-separation basis, and Q4 2025 is left blank because the reports before and after use different bases.
  • No market prices are used. The only market value is the figure on each 10-K cover at its reference date.
  • 買収の効果は取り除いていない。報告書に買収した会社を除いた売上高・利益がないため、成長率・利益率の変化に買収が混ざっている。
  • 会計年度が異なる。FactSetは8月決算、他は12月決算。
  • 純売上高の定義は取引所が決めた行。何を通過費用とみなすかは取引所ごとに異なる。
  • S&P Globalは2026年に1つの事業を切り離した。直近の会計年度(2025)は切り離し前の基準で、2025年第4四半期は前後の報告書の基準が異なるため空欄にした。
  • 株価は使っていない。唯一の市場価値は各10-Kの表紙の基準日の値。

출처: U.S. SEC EDGAR (재무제표)Source: U.S. SEC EDGAR (financial statements)出所:U.S. SEC EDGAR(財務諸表)